Reference number
2617-H

SPECIALTY QUANTITY LIMIT PROGRAM

BRAFTOVI (encorafenib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Braftovi 50 mg capsules	120 per 30 days	Initial dose: 450 mg once daily Dose adjustments due to adverse reactions • First reduction: 300 mg once daily • Second reduction: 200 mg once daily and discontinue if not tolerated Dose adjustments due to drug interactions: • For use with a strong CYP3A4 inhibitor: Reduce the Braftovi dose to one-third of the dose prior to concurrent use • For use with a moderate CYP3A4 inhibitor: Reduce the Braftovi dose to one-half of the dose prior to concurrent use.
Braftovi 75 mg capsules	180 per 30 days	

III. REFERENCES

1. Braftovi [package insert]. Boulder, CO: Array BioPharma, Inc.; June 2018.

CVS caremark™